Abstract:Background: The COVID-19 pandemic is caused by the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). SARS-CoV-2 is disseminated by respiratory aerosols. The virus uses the spike protein to target epithelial cells by binding to the ACE2 receptor on the host cells. As a result, effective vaccines must target the viral spike glycoprotein. However, the appearance of an Omicron variant with 32 mutations in its spike protein raises questions about the vaccine's efficacy. Vaccines are critical in boosting immunity, lowering COVID-19-related illnesses, reducing the infectious burden on the healthcare system, and reducing economic loss, according to current data. An efficient vaccination campaign is projected to increase innate and adaptive immune responses, offering better protection against SARS-CoV-2 variants. Main body: The presence of altered SARS-CoV-2 variants circulating around the world puts the effectiveness of vaccines already on the market at risk. The problem is made even worse by the Omicron variant, which has 32 mutations in its spike protein. Experts are currently examining the potential consequences of commercial vaccines on variants. However, there are worries about the vaccines' safety, the protection they provide, and whether future structural changes are required for these vaccines to be more effective. As a result of these concerns, new vaccines based on modern technology should be developed to guard against the growing SARS-CoV-2 variations. Conclusion: The choice of a particular vaccine is influenced by several factors including mode of action, storage conditions, group of the vaccinee, immune response mounted, cost, dosage protocol, age, and side effects. Currently, seven SARS-CoV-2 vaccine platforms have been developed. This comprises of inactivated viruses, messenger RNA (mRNA), DNA vaccines, protein subunits, nonreplicating and replicating vector viral-like particles (VLP), and live attenuated vaccines. This review focuses on the SARS-CoV-2 mutations, variants of concern (VOCs), and advances in vaccine technologies.

The Variation of SARS-CoV-2 and Advanced Research on Current Vaccines

The Challenge of Emerging SARS-CoV-2 Mutants to Vaccine Development

SARS-CoV-2: Mapping its features that made it as a unique virus

Genomic variation, origin tracing, and vaccine development of SARS-CoV-2: A systematic review

Understanding the Secret of SARS-CoV-2 Variants of Concern/Interest and Immune Escape

Challenges in Emerging Vaccines and Future Promising Candidates against SARS-CoV-2 Variants

COVID-19: Understanding the New Variants of Concern

The way of SARS-CoV-2 vaccine development: success and challenges

COVID-19 Variants and Vaccine Development

Research progress in spike mutations of SARS‐CoV‐2 variants and vaccine development

COVID-19: An Overview of SARS-CoV-2 Variants—The Current Vaccines and Drug Development

Recent Advances in Vaccine Development of Severe Acute Respiratory Syndrome Coronavirus 2

A systematic review of SARS-CoV-2 vaccine candidates

SARS-CoV-2 Variants, Vaccines, and Host Immunity

Scope of SARS-CoV-2 variants, mutations, and vaccine technologies

Vaccines for COVID-19: A Systematic Review of Immunogenicity, Current Development, and Future Prospects

Evaluation of Immunoprotection Against Coronavirus Disease 2019: Novel Variants, Vaccine Inoculation, and Complications

The COVID-19 Vaccines: Recent Development, Challenges and Prospects

Novel receptor, mutation, vaccine, and establishment of coping mode for SARS-CoV-2: current status and future

COVID‐19 vaccine: recent advancements and future prospects

SARS-CoV-2 Variants, Immune Escape, and Countermeasures